Summary
Stryker Corporation reported a solid third quarter for fiscal year 2025, with net sales increasing by 10.3% year-over-year to $6.06 billion. This growth was driven by a robust 9.6% increase in constant currency, with nearly all segments contributing to higher unit volumes. The MedSurg and Neurotechnology segment showed particularly strong performance, with a 14.4% reported sales increase, bolstered by the recent acquisition of Inari Medical. The Orthopaedics segment also saw positive growth, albeit at a more moderate pace of 3.9%. Net earnings for the quarter were $859 million, a slight increase from $834 million in the prior year, resulting in diluted earnings per share of $2.22, up from $2.16. While overall operating income saw a marginal increase, the operating income margin slightly compressed due to various factors including integration costs from the Inari acquisition and increased selling, general, and administrative expenses. Despite these pressures, the company maintains a strong financial position with healthy cash flow from operations.
Financial Highlights
52 data points| Revenue | $6.06B |
| Cost of Revenue | $2.21B |
| Gross Profit | $3.85B |
| R&D Expenses | $410.00M |
| SG&A Expenses | $2.04B |
| Operating Expenses | $2.72B |
| Operating Income | $1.14B |
| Interest Expense | $157.00M |
| Net Income | $859.00M |
| EPS (Basic) | $2.25 |
| EPS (Diluted) | $2.22 |
| Shares Outstanding (Basic) | 382.40M |
| Shares Outstanding (Diluted) | 386.70M |
Key Highlights
- 1Net sales grew 10.3% year-over-year to $6.06 billion, with 9.6% growth in constant currency, indicating strong underlying demand across segments.
- 2MedSurg and Neurotechnology segment sales increased by 14.4%, significantly boosted by the acquisition of Inari Medical.
- 3Diluted EPS rose to $2.22 from $2.16 in the prior year's third quarter, demonstrating improved profitability on a per-share basis.
- 4Operating income saw a modest increase, but the operating margin compressed slightly, reflecting investment in growth and acquisition integration.
- 5The company generated strong cash flow from operations, totaling $2.9 billion for the nine months ended September 30, 2025, supporting financial flexibility.
- 6Stryker continued to manage its debt effectively, issuing new notes and maintaining compliance with credit facility covenants.
- 7Goodwill and other impairments increased significantly compared to the prior year, primarily related to the sale of the Spinal Implants business.